Noonan syndrome (NS) is a developmental syndrome caused by germline mutations in the Ras signaling pathway. No association has been shown between NS and pediatric colorectal cancer (CRC). We report the case of CRC in a pediatric patient with NS. The patient underwent whole genome sequencing. A germline SOS1 mutation c.1310T>C (p. Ile437Thr) confirmed NS diagnosis.
INTRODUCTION
Noonan syndrome (NS) is a developmental syndrome with an estimated prevalence of 1 in 1000-2500 and characterized by craniofacial abnormalities, cardiac defects, and cognitive delay. 1 NS is caused by germline mutations affecting the Ras signaling pathway, as are neurofibromatosis 1 (NF1) and several other syndromes that are collectively referred to as Rasopathies. 2 The Ras signaling pathway is a ubiquitous intracellular signaling pathway that has been shown to play a central role in the pathogenesis of adult colorectal cancer (CRC). Interestingly, Rasopathies carry an inconsistent cancer predisposition ranging from an elevated risk of neurologic-type tumors in children with NF1 to a mild, almost exclusive risk for hematologic malignancies in patients of all ages with NS. [3] [4] [5] Germline mutations affecting Ras signaling pathway proteins have not been reported to carry a predisposition to CRC. Only three cases of patients with NS with CRC have ever been reported and none in the pediatric population. 3 16, 17 Three point mutations with clinical significance were identified, one germline mutation and two somatic mutations in the tumor sample. The germline mutation in SOS1 and somatic mutation in TP53 encoded missense mutations causing a single amino acid change in the protein product. The somatic mutation in NCOR1 encoded a nonsense mutation causing a truncation of the protein product.
TA B L E 1 Clinically significant mutations identified from genome-wide analysis

Gene
Pathology of the surgical specimens showed colon adenocarcinoma, 
RESULTS AND DISCUSSION
Integrative clinical sequencing revealed three mutations with clinical significance, one in the germline and two somatic mutations in the tumor sample (Table 1) . Four somatic point mutations were also identified in the tumor sample (Supplementary Table S1 Motifs within these regions have been shown to be necessary for binding to nuclear hormone receptors. NCOR1 also plays an important role in acute promyelocytic leukemia therapy. Retinoic acid competes with NCOR1 for transcription factor RAR alpha binding. 15 Recently, large-scale genomic studies have identified NCOR1 driver mutations in breast cancer and hepatocarcinoma. 16, 17 Of note, no mutations affecting the Wnt signaling pathway were identified in the germline or the tumor. The Wnt pathway plays an important pathogenic role in CRC, with 93% of all CRC tumors affecting this pathway have mutations. 6, 11 Germline mutations in this pathway cause hereditary CRC syndromes including familial adenomatous polyposis and juvenile polyposis.
The genetics of developmental syndromes have offered important insight into cancer, and the overlapping manifestations been described as a continuous spectrum (Figure 1) . 6, 7, 18, 19 Variations in genotype likely disrupt development by affecting the interplay between different signal transduction and epigenetic pathways. Subsequent compensation may explain survival as well as nonintuitive cancer risks. 2, [18] [19] [20] 
